Premium
IMMUNE AND VIRUS‐SPECIFIC RESPONSES IN PARTICIPANTS WITH PRIMARY EFFUSION LYMPHOMA RECEIVING LENALIDOMIDE, DOSE‐ADJUSTED EPOCH, AND RITUXIMAB (EPOCH‐R 2 )
Author(s) -
Lurain K,
Roshan R,
Ramaswami R,
Mangusan R,
Widell A,
Ekwede I,
Ziegelbauer J. M,
Uldrick T. S,
Whitby D,
Yarchoan R,
Krug L. T
Publication year - 2021
Publication title -
hematological oncology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.918
H-Index - 44
eISSN - 1099-1069
pISSN - 0278-0232
DOI - 10.1002/hon.5_2880
Subject(s) - medicine , primary effusion lymphoma , rituximab , lenalidomide , gastroenterology , lymphoma , cd38 , vincristine , oncology , immunology , cyclophosphamide , chemotherapy , cd34 , biology , stem cell , multiple myeloma , genetics